Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Biotechnology

Delix Therapeutics

Mark Rus

Milan Chytil

Kurt Rasmussen

Eliseo Salinas

Matt Gorman

Tricia Mccall

Sharon Engel

Retsina Meyer

David Olson

The Corporate Strategy team at Delix Therapeutics is responsible for driving the company's long-term vision and growth initiatives. This includes market analysis, competitive intelligence, strategic partnerships, and guiding the company's preclinical and clinical development programs. The team ensures alignment between scientific advancements and business objectives to achieve the goal of alleviating mental suffering with safe, non-hallucinogenic psychoplastogen compounds.

Corporate Strategy

Advisory

Leadership Team

Corporate Strategy

About

Team members

Other teams at Delix Therapeutics

Advisory

Leadership Team